{"success":true,"data":{"pressRelease":{"id":"5473","rtpr_id":"nGNX55CnB5","ticker":"SUPN","exchange":"NASDAQ","all_tickers":["SUPN"],"title":"Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026","author":"Globe Newswire","published_at":"2026-04-22T20:15:00.292Z","article_body":"ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,\nInc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and\ncommercializing products for the treatment of central nervous system (CNS)\ndiseases, today announced that it will report first quarter 2026 financial and\nbusiness results after the market closes on Tuesday, May 5, 2026.\n\nJack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO,\nwill host a conference call and webcast on Tuesday, May 5, 2026, at 4:30 p.m.\nET to discuss these results. Following management’s prepared remarks and\ndiscussion of business results, the call will be open for questions.\n\nA live webcast will be accessible in the Events & Presentations section of the\nCompany’s Investor Relations website at www.supernus.com/Investors.\n\nParticipants may also pre-register any time before the call here\n(https://www.globenewswire.com/Tracker?data=OXn6nXiTOWEO6O2BI3n__z2VH8NoMJGC5taK32Ubk9algZmh66DOUmZOZVkvrWL89dG_CSf102sQIfB3QCU3GRpMUkM8YKhV1awrBzYeNF6Q4k2SskHBIazKqQyDRMbpW0OBIb7LDbOIVIEKCykuIxxKBksc2dlif6LrthOv5nI=).\nOnce registration is completed, participants will be provided a dial-in number\nwith a personalized conference code to access the call. Please dial in 15\nminutes prior to the start time.\n\nFollowing the live call, a replay will be available on the Company's Investor\nRelations website at www.supernus.com/Investors. The webcast will be available\non the Company’s website for 60 days following the live call.\n\nAbout Supernus Pharmaceuticals, Inc.\n\nSupernus Pharmaceuticals is a biopharmaceutical company focused on developing\nand commercializing products for the treatment of central nervous system (CNS)\ndiseases.\n\nOur diverse neuroscience portfolio includes approved treatments for\nattention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's\ndisease (PD) patients receiving levodopa-based therapy, hypomobility in PD,\npostpartum depression (PPD), epilepsy, migraine, cervical dystonia, and\nchronic sialorrhea. We are developing a broad range of novel product\ncandidates for CNS disorders.\n\nFor more information, please visit www.supernus.com.\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. These statements do not\nconvey historical information but relate to predicted or potential future\nevents that are based upon management's current expectations. These statements\nare subject to risks and uncertainties that could cause actual results to\ndiffer materially from those expressed or implied by such statements. In\naddition to the factors mentioned in this press release, such risks and\nuncertainties include, but are not limited to, the Company's ability to\nsustain and increase its profitability; the Company's ability to raise\nsufficient capital to fully implement its corporate strategy; the\nimplementation of the Company's corporate strategy; the Company's future\nfinancial performance and projected expenditures; the Company's ability to\nincrease the number of prescriptions written for each of its products, and the\nproducts of its subsidiaries; the Company's ability to increase its net\nrevenue from its products, and the products of its subsidiaries; the Company's\nability to commercialize its products, and the products of its subsidiaries\nthe Company's ability to enter into future collaborations with pharmaceutical\ncompanies and academic institutions or to obtain funding from government\nagencies; the Company's product research and development activities, including\nthe timing and progress of the Company's clinical trials, and projected\nexpenditures; the Company's ability to receive, and the timing of any receipt\nof, regulatory approvals to develop and commercialize the Company's product\ncandidates; the Company's ability to protect its intellectual property and the\nintellectual property of its subsidiaries and operate its business without\ninfringing upon the intellectual property rights of others; the Company's\nexpectations regarding federal, state and foreign regulatory requirements; the\ntherapeutic benefits, effectiveness and safety of the Company's product\ncandidates; the accuracy of the Company's estimates of the size and\ncharacteristics of the markets that may be addressed by its product\ncandidates; the Company's ability to increase its manufacturing capabilities\nfor its products and product candidates; the Company's projected markets and\ngrowth in markets; the Company's product formulations and patient needs and\npotential funding sources; the Company's staffing needs; changes to laws and\nregulations applicable to our industry, the impact of macroeconomic factors,\nsuch as economic downturns or uncertainty, international conflict, trade\ndisputes and tariffs; and other risk factors set forth from time to time in\nthe Company's filings with the Securities and Exchange Commission made\npursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as\namended. The Company undertakes no obligation to update the information in\nthis press release to reflect events or circumstances after the date hereof or\nto reflect the occurrence of anticipated or unanticipated events.\n\nCONTACTS:\n\nJack A. Khattar, President and CEO\nTimothy C. Dec, Senior Vice President and CFO\nSupernus Pharmaceuticals, Inc.\n(301) 838-2591\n\nOr\n\nINVESTOR CONTACT:\n\nPeter Vozzo \nICR Healthcare\n(443) 213-0505\npeter.vozzo@icrhealthcare.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1fc58442-511b-40c2-a8c0-f1e78b8437b4)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX55CnB5","title":"Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026","author":"Globe Newswire","ticker":"SUPN","created":"2026-04-22T20:15:00.292Z","tickers":["SUPN"],"exchange":"NASDAQ","article_body":"ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,\nInc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and\ncommercializing products for the treatment of central nervous system (CNS)\ndiseases, today announced that it will report first quarter 2026 financial and\nbusiness results after the market closes on Tuesday, May 5, 2026.\n\nJack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO,\nwill host a conference call and webcast on Tuesday, May 5, 2026, at 4:30 p.m.\nET to discuss these results. Following management’s prepared remarks and\ndiscussion of business results, the call will be open for questions.\n\nA live webcast will be accessible in the Events & Presentations section of the\nCompany’s Investor Relations website at www.supernus.com/Investors.\n\nParticipants may also pre-register any time before the call here\n(https://www.globenewswire.com/Tracker?data=OXn6nXiTOWEO6O2BI3n__z2VH8NoMJGC5taK32Ubk9algZmh66DOUmZOZVkvrWL89dG_CSf102sQIfB3QCU3GRpMUkM8YKhV1awrBzYeNF6Q4k2SskHBIazKqQyDRMbpW0OBIb7LDbOIVIEKCykuIxxKBksc2dlif6LrthOv5nI=).\nOnce registration is completed, participants will be provided a dial-in number\nwith a personalized conference code to access the call. Please dial in 15\nminutes prior to the start time.\n\nFollowing the live call, a replay will be available on the Company's Investor\nRelations website at www.supernus.com/Investors. The webcast will be available\non the Company’s website for 60 days following the live call.\n\nAbout Supernus Pharmaceuticals, Inc.\n\nSupernus Pharmaceuticals is a biopharmaceutical company focused on developing\nand commercializing products for the treatment of central nervous system (CNS)\ndiseases.\n\nOur diverse neuroscience portfolio includes approved treatments for\nattention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's\ndisease (PD) patients receiving levodopa-based therapy, hypomobility in PD,\npostpartum depression (PPD), epilepsy, migraine, cervical dystonia, and\nchronic sialorrhea. We are developing a broad range of novel product\ncandidates for CNS disorders.\n\nFor more information, please visit www.supernus.com.\n\nForward-Looking Statements\n\nThis press release includes forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995. These statements do not\nconvey historical information but relate to predicted or potential future\nevents that are based upon management's current expectations. These statements\nare subject to risks and uncertainties that could cause actual results to\ndiffer materially from those expressed or implied by such statements. In\naddition to the factors mentioned in this press release, such risks and\nuncertainties include, but are not limited to, the Company's ability to\nsustain and increase its profitability; the Company's ability to raise\nsufficient capital to fully implement its corporate strategy; the\nimplementation of the Company's corporate strategy; the Company's future\nfinancial performance and projected expenditures; the Company's ability to\nincrease the number of prescriptions written for each of its products, and the\nproducts of its subsidiaries; the Company's ability to increase its net\nrevenue from its products, and the products of its subsidiaries; the Company's\nability to commercialize its products, and the products of its subsidiaries\nthe Company's ability to enter into future collaborations with pharmaceutical\ncompanies and academic institutions or to obtain funding from government\nagencies; the Company's product research and development activities, including\nthe timing and progress of the Company's clinical trials, and projected\nexpenditures; the Company's ability to receive, and the timing of any receipt\nof, regulatory approvals to develop and commercialize the Company's product\ncandidates; the Company's ability to protect its intellectual property and the\nintellectual property of its subsidiaries and operate its business without\ninfringing upon the intellectual property rights of others; the Company's\nexpectations regarding federal, state and foreign regulatory requirements; the\ntherapeutic benefits, effectiveness and safety of the Company's product\ncandidates; the accuracy of the Company's estimates of the size and\ncharacteristics of the markets that may be addressed by its product\ncandidates; the Company's ability to increase its manufacturing capabilities\nfor its products and product candidates; the Company's projected markets and\ngrowth in markets; the Company's product formulations and patient needs and\npotential funding sources; the Company's staffing needs; changes to laws and\nregulations applicable to our industry, the impact of macroeconomic factors,\nsuch as economic downturns or uncertainty, international conflict, trade\ndisputes and tariffs; and other risk factors set forth from time to time in\nthe Company's filings with the Securities and Exchange Commission made\npursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as\namended. The Company undertakes no obligation to update the information in\nthis press release to reflect events or circumstances after the date hereof or\nto reflect the occurrence of anticipated or unanticipated events.\n\nCONTACTS:\n\nJack A. Khattar, President and CEO\nTimothy C. Dec, Senior Vice President and CFO\nSupernus Pharmaceuticals, Inc.\n(301) 838-2591\n\nOr\n\nINVESTOR CONTACT:\n\nPeter Vozzo \nICR Healthcare\n(443) 213-0505\npeter.vozzo@icrhealthcare.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1fc58442-511b-40c2-a8c0-f1e78b8437b4)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-22T20:15:00.345937342Z","server_sent_at_ms":1776888900345},"received_at":"2026-04-22T20:15:03.246Z","source_url":null},"analysis":{"id":"4000","press_release_id":"5473","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Supernus Pharmaceuticals announced it will report first quarter 2026 financial results after the market closes on May 5, 2026.\n\nPresident and CEO Jack Khattar and SVP and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.\n\nA live and replay webcast will be available on the company's Investor Relations website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":""},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Jack Khattar","role":"President and CEO"},{"name":"Tim Dec","role":"Senior Vice President and CFO"},{"name":"Peter Vozzo","role":"Investor Contact"}],"products":[],"companies":[{"name":"Supernus Pharmaceuticals, Inc.","ticker":"SUPN"},{"name":"ICR Healthcare","relationship":"Investor Relations firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine earnings announcement scheduling without data or guidance. Material impact is negligible until results are actually reported."},"tickerRelevance":{"others":[],"primary":"SUPN"},"eventTypeSecondary":[]},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Supernus Pharmaceuticals announced it will report first quarter 2026 financial results after the market closes on May 5, 2026.\n\nPresident and CEO Jack Khattar and SVP and CFO Tim Dec will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results.\n\nA live and replay webcast will be available on the company's Investor Relations website.","key_figures":{},"named_entities":{"people":[{"name":"Jack Khattar","role":"President and CEO"},{"name":"Tim Dec","role":"Senior Vice President and CFO"},{"name":"Peter Vozzo","role":"Investor Contact"}],"products":[],"companies":[{"name":"Supernus Pharmaceuticals, Inc.","ticker":"SUPN"},{"name":"ICR Healthcare","relationship":"Investor Relations firm"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-22T22:45:49.120Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.423Z"}},"durationMs":15730,"modelName":"glm-4.7"}}